New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 20, 2014
10:08 EDTLCILannett does not expect study to significantly impact Digoxin sales
Lannett commented on the utilization of Digoxin, following a recently published abstract in the Journal of the American College of Cardiology, which suggested a potential increased risk of mortality in patients with newly diagnosed atrial fibrillation. The abstract was based on data of the TREAT-AF study from the U.S. Department of Veterans Affairs healthcare system, the company said. "Digoxin has long been an important treatment option for cardiovascular disease,” said Arthur Bedrosian, CEO of Lannett. “As with most medications, we believe medical care providers will continue to prescribe Digoxin unless a more effective alternative medication is available. The company said it does not expect prescriptions of Digoxin to be significantly impacted by the findings of the JACC study. Digoxin currently represents less than 10 percent of the company’s net revenues." Bedrosian went on to say that the company has "implemented a comprehensive strategy to expand and diversify its product offering by developing products internally, forming strategic alliances and acquiring products complementary to its business."
News For LCI From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 29, 2014
14:29 EDTLCILannett announces FDA approval of Letrozole tablets
Subscribe for More Information
October 23, 2014
07:56 EDTLCILannett sees Q1 EPS 91c-94c, consensus 77c
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use